This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Forschungsverbund Berlin E.v., Max-Delbruck-Centrum Fur Molekulare Medizin. Active years: 2011.
Company Filing History:
1 out of 93 
1 out of 32 Years Active: 2011
Title: Klaus Hellmuth: Innovator in Pharmaceutical Compositions
Introduction
Klaus Hellmuth is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of small molecule protein tyrosine phosphatase inhibitors. His work focuses on addressing critical health issues, including cancer and other proliferative diseases.
Latest Patents
Klaus Hellmuth holds a patent for "Shp-2 inhibitors and pharmaceutical compositions comprising them." This invention relates to small molecule inhibitors of protein tyrosine phosphatase, specifically Shp-2 inhibitors. The patent outlines the use of these compounds for treating phosphatase-mediated diseases, with a strong emphasis on cancer and metastasis. The invention also details a method for treating various diseases by administering a therapeutically effective amount of the compounds.
Career Highlights
Throughout his career, Klaus Hellmuth has worked with prominent research institutions, including Forschungsverbund Berlin e.V. and Max-Delbrück-Centrum für Molekulare Medizin. His expertise in the pharmaceutical field has allowed him to contribute to groundbreaking research and development.
Collaborations
Klaus has collaborated with esteemed colleagues such as Walter Birchmeier and Joerg Rademann. These partnerships have further enhanced his research and innovation in the pharmaceutical sector.
Conclusion
Klaus Hellmuth's contributions to the field of pharmaceuticals, particularly through his patent on Shp-2 inhibitors, highlight his role as an innovator in addressing critical health challenges. His work continues to impact the treatment of serious diseases, showcasing the importance of innovation in medicine.